Xun Shi

发表

Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

Chen Lin, Xin-min Yu, Junrong Yan, 2022, BMC cancer.

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

P. A. Futreal, I. Wistuba, Yamei Chen, 2019, Oncogene.

Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation

Yun Fan, Shifeng Yang, Xin-min Yu, 2018, Journal of Cancer.

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing

Xue Wu, Y. Shao, Yiping Zhang, 2016, Oncotarget.

Salvage treatment with apatinib for advanced non-small-cell lung cancer

Yiping Zhang, Z. Song, G. Lou, 2017, OncoTargets and therapy.

Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study

Wenfeng Li, Ming Chen, Jun Zhao, 2019, British Journal of Cancer.

Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis.

Jun Zhao, Xin-min Yu, Ying Jin, 2014, Journal of cancer research and therapeutics.

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer

Y. Shao, Jun Zhao, Ying-yu Jin, 2020, Frontiers in Oncology.

A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer.

Yamei Chen, Xin-min Yu, Ying Jin, 2018, Oncology letters.

Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment.

Jun Zhao, Xin-min Yu, Ying Jin, 2014, Clinical therapeutics.

Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.

Jun Zhao, Chen Lin, Xin-min Yu, 2019, Lung cancer.

Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.

Xue Wu, Y. Shao, Q. Ou, 2018, Lung cancer.

Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients

Jun Zhao, Xin-min Yu, Xun Shi, 2014, World Journal of Surgical Oncology.

Prognostic value of programed death ligand 1 in patients with solid tumors: A meta-analysis.

Jun Zhao, Ying Jin, Xun Shi, 2015, Journal of cancer research and therapeutics.

JCES01.14 Mutational Profiling of Non-Small-Cell Lung Cancer Patients Resistant to First-Generation EGFR Tyrosine Kinase Inhibitors Using next Generation Sequencing

Yiping Zhang, G. Lou, Ying Jin, 2017 .

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

Yan Zhang, Yanqiu Zhao, Xueyan Zhang, 2023, Journal for ImmunoTherapy of Cancer.